Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Background: The biomarkers of immune checkpoint inhibitors (ICIs) efficacy and safety are still urgently needed. As cytokines are easily detected and monitored in circulation, they could be used as potential predictors of response and immune-related adverse events (irAEs) for ICIs therapy. Methods:...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Katarina Mirjačić Martinović, Ana Vuletić, Nevena Tišma Miletić, Irina Besu Žižak, Jelena Milovanović, Suzana Matković, Vladimir Jurišić
Formatua:	Artikulua
Hizkuntza:	English
Argitaratua:	Elsevier 2023-12-01
Saila:	Translational Oncology
Gaiak:	Metastatic melanoma patients BRAF wild type Pembrolizumab Cytokines Monitoring Outcome predictors
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S1936523323001857

Antzeko izenburuak

Complete response in a patient with BRAF-mutant metastatic melanoma achieved with the multidisciplinary approach: a case report
nork: Hana Garaj, et al.
Argitaratua: (2024-01-01)

Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
nork: Senar Ebinç, et al.
Argitaratua: (2023-09-01)

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
nork: Wu L, et al.
Argitaratua: (2021-02-01)

Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients
nork: Katarina Mirjačić Martinović, et al.
Argitaratua: (2023-04-01)

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives
nork: Dugan MM, et al.
Argitaratua: (2024-07-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
nork: Polsky David, et al.
Argitaratua: (2004-12-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
nork: Francesca Consoli, et al.
Argitaratua: (2020-07-01)

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study
nork: Jacek Calik, et al.
Argitaratua: (2024-01-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
nork: Justin C. Moser, et al.
Argitaratua: (2019-12-01)

Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease
nork: Xiang Dan, et al.
Argitaratua: (2024-04-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
nork: I. V. SAMOILENKO, et al.
Argitaratua: (2017-06-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
nork: Ernesto Rossi, et al.
Argitaratua: (2023-01-01)

A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14C] encorafenib in healthy male subjects
nork: Lance Wollenberg, et al.
Argitaratua: (2023-10-01)

Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
nork: Bartoušková Marie, et al.
Argitaratua: (2020-08-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
nork: Yu. S. Shakh-Paronyants, et al.
Argitaratua: (2023-03-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
nork: Dahlia Fedele, et al.
Argitaratua: (2024-01-01)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
nork: Saba S. Shaikh, et al.
Argitaratua: (2022-11-01)

Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naïve and previously infected individuals
nork: Milena Cavic, et al.
Argitaratua: (2023-04-01)

Melanoma: BRAFi Rechallenge
nork: Christoforos S. Kosmidis, et al.
Argitaratua: (2023-05-01)

Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab
nork: Rozala Arko, et al.
Argitaratua: (2022-07-01)

MEK inhibitors for the treatment of NRAS mutant melanoma
nork: Sarkisian S, et al.
Argitaratua: (2018-08-01)

The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome
nork: Lazaro Hiram Betancourt, et al.
Argitaratua: (2021-07-01)

Current State of Target Treatment in BRAF Mutated Melanoma
nork: Enrica Teresa Tanda, et al.
Argitaratua: (2020-07-01)

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report
nork: Marco Ghezzi, et al.
Argitaratua: (2020-03-01)

Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations
nork: Ahmed Temirak, et al.
Argitaratua: (2025-02-01)

Update on the treatment of BRAFmut metastatic melanoma and future perspectives
nork: Peter Mohr, et al.
Argitaratua: (2025-03-01)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
nork: Karam Khaddour, et al.
Argitaratua: (2021-06-01)

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study
nork: Igor V. Samoylenko, et al.
Argitaratua: (2024-10-01)

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
nork: Adi Kartolo, et al.
Argitaratua: (2022-03-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
nork: Simeng Zhang, et al.
Argitaratua: (2023-01-01)

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report
nork: Clara So, et al.
Argitaratua: (2022-05-01)

Braf protein mutation and its significancy within patients with melanoma
nork: Julia Kuchnicka, et al.
Argitaratua: (2022-08-01)

Treatment of Advanced Melanoma: Past, Present and Future
nork: Taku Fujimura, et al.
Argitaratua: (2020-09-01)

Comparison of Two Rapid Assays for the Detection of <i>BRAF</i> V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes
nork: Elodie Long-Mira, et al.
Argitaratua: (2022-03-01)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
nork: Walid Shalata, et al.
Argitaratua: (2023-02-01)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
nork: Nakul Dar, et al.
Argitaratua: (2023-08-01)

Tyrosine kinase inhibitors via nasogastric tube may resolve severe ileus secondary to melanoma: A case report
nork: Lena Groennendijk, et al.
Argitaratua: (2022-06-01)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
nork: Francesco Serra, et al.
Argitaratua: (2021-08-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
nork: O. I. Kit, et al.
Argitaratua: (2016-06-01)

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
nork: Sim Vermeulen, et al.
Argitaratua: (2021-04-01)